GSK plc (NYSE:GSK) Shares Sold by Integrated Wealth Concepts LLC

Integrated Wealth Concepts LLC decreased its holdings in shares of GSK plc (NYSE:GSK) by 2.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,006 shares of the pharmaceutical company’s stock after selling 346 shares during the quarter. Integrated Wealth Concepts LLC’s holdings in GSK were worth $695,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in GSK. Eastern Bank acquired a new stake in GSK during the third quarter worth $26,000. Concord Wealth Partners increased its stake in GSK by 231.8% during the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after acquiring an additional 547 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in GSK during the second quarter worth $37,000. Fortitude Family Office LLC purchased a new position in shares of GSK during the third quarter worth $42,000. Finally, PrairieView Partners LLC purchased a new position in shares of GSK during the second quarter worth $47,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on GSK shares. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. StockNews.com lowered GSK from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 4th. Barclays upgraded GSK to a “hold” rating in a research report on Tuesday, August 27th. Finally, Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and lowered their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Seven research analysts have rated the stock with a hold rating, one has assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $43.25.

Insider Buying and Selling

In other GSK news, major shareholder Plc Gsk acquired 2,791,930 shares of the stock in a transaction dated Friday, September 27th. The stock was acquired at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the transaction, the insider now owns 16,775,691 shares in the company, valued at $134,205,528. The trade was a 19.97 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.00% of the stock is currently owned by insiders.

GSK Trading Up 4.2 %

GSK opened at $36.01 on Tuesday. GSK plc has a 12 month low of $32.83 and a 12 month high of $45.92. The stock has a market capitalization of $74.63 billion, a price-to-earnings ratio of 23.38, a PEG ratio of 1.33 and a beta of 0.64. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The business has a fifty day moving average price of $36.56 and a 200 day moving average price of $39.50.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be paid a dividend of $0.3928 per share. This represents a $1.57 annualized dividend and a yield of 4.36%. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date is Friday, November 15th. GSK’s payout ratio is presently 99.35%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.